188Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study
The aim of this study was to investigate the feasibility of administering increasing activities of 188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodol (188Re-HDD/lipiodol) for the treatment of hepatocellular carcinoma (HCC) in patients with well-compensated cirrhosis.
The activity levels were increased by 1.1 GBq/step after a 6-week interval without unacceptable adverse events in at least five consecutive patients. Absorbed doses to the various organs were calculated according to the MIRD formalism, based on three gamma-scintigraphic studies. Response was assessed by means of MRI and alpha-fetoprotein (AFP) monitoring.
Thirty-five treatments were carried out in 28 patients. Activities from 4.8 to 7.0 GBq 188Re-HDD/lipiodol were administered via a transfemoral catheter. The mean absorbed dose to the liver (including tumour) was 7.6±2.2, 9.8±4.9 and 15.2±4.9 Gy for the 4.8-, 5.9- and 7.0-GBq groups, respectively. Treatment was well tolerated at all activity levels. Further escalation of the administered activity was not feasible owing to limitations related to the radiolabelling procedure. Response assessment on MRI showed partial response, stable disease and disease progression in 1, 28 and 2 assessable treatments, respectively. In 8 of 17 treatment sessions with an initially elevated AFP, a reduction ranging from 19% to 97% was observed 6 weeks later.
Following the intra-arterial administration of 4.8–7.0 GBq 188Re-HDD/lipiodol in patients with HCC and well-compensated liver cirrhosis, no severe adverse events occurred. Further escalation was not feasible owing to limitations in the radiolabelling procedure.
KeywordsHepatocellular carcinoma Lipiodol Rhenium-188 Radionuclide therapy HDD
The authors would like to thank the IRE (Institut des Radio-Eléments, Fleurus, Belgium) for their technical assistance. The work was supported by a grant of the Bijzonder Onderzoeksfonds (Ghent University, No 011D9501).
- 12.Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002;1:5–11Google Scholar
- 17.Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF Jr. Simple new method for effective concentration of Re-188 solutions from alumina-based W-188–Re-188 generator. J Nucl Med 2000;4:1271–8Google Scholar
- 19.Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1991Google Scholar
- 23.The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751–5Google Scholar
- 27.Lambert B, Praet M, Vanlangenhove P, Troisi R, de Hemptinne B, Gemmel F, et al. Radiolabelled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome. Cancer Biother Radiopharm 2005:20:209–14CrossRefPubMedGoogle Scholar
- 28.Boschi A, Uccelli L, Duatti A, Colamussi P, Cittanti C, Filice A, et al. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004; 25:691–9CrossRefPubMedGoogle Scholar